PMID- 35844767
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220719
IS  - 2589-5370 (Electronic)
IS  - 2589-5370 (Linking)
VI  - 51
DP  - 2022 Sep
TI  - Safety and efficacy of mesenchymal stem cells in severe/critical patients with 
      COVID-19: A systematic review and meta-analysis.
PG  - 101545
LID - 10.1016/j.eclinm.2022.101545 [doi]
LID - 101545
AB  - BACKGROUND: The present study aims to better understand the efficacy and safety 
      of mesenchymal stromal cells (MSCs) in treating severe/critical patients with 
      COVID-19. METHODS: PubMed, the Cochrane Library, and the Chinese electronic 
      database CNKI were searched from inception up to Dec 19, 2021. Original 
      comparative studies for MSC treatment + standard treatment for severe/critical 
      patients with COVID-19, with placebo or standard treatment as the control group, 
      were included. The primary outcomes were in-hospital mortality and adverse events 
      (AEs). A meta-analysis was performed to compare the mortality rates between the 
      two groups. Then, a subgroup analysis was performed according to the category of 
      the disease (severe or critical) and MSC dose. Afterwards, a descriptive analysis 
      was performed for AEs and secondary outcomes. The funnel plot and Egger's test 
      were used for the publication bias assessment. FINDINGS: Compared to placebo or 
      standard care, MSCs provide significant benefit in the treatment of patients with 
      severe/critical COVID-19, in terms of in-hospital mortality rate (odds ratio: 
      0.52, 95% CI 0.32-0.84), with very low heterogeneity (P=0.998 [Q test], I 
      (2)=0.0%) and less AEs. No significant difference was found in mortality rate due 
      to the different disease categories or MSC doses. Furthermore, no publication 
      bias was found. INTERPRETATION: The present study demonstrates that MSCs are 
      highly likely to reduce mortality and are safe to use for patients with severe or 
      critical COVID-19, regardless of whether 1-3 doses are applied. However, due to 
      the small sample size of the included studies, further high-quality, large-scale 
      trials are needed to confirm this statement in the future. FUNDING: The National 
      Key Research and Development Program of China (No. 2020YFC0860900), the Science 
      and Technology Project of Wuhan (No. 2020020602012112), the Tianjin Science and 
      Technology Research Program (18PTSYJC00070 and 16PTWYHZ00030), Haihe Laboratory 
      of Cell Ecosystem Innovation Fund (HH22KYZX0046), and the Tianjin Free Trade Zone 
      Innovation Development Project (ZMCY-03-2021002-01) funded the study. We are also 
      grateful for the support from the 3551 Talent Plan of China Optics Valley.
CI  - (c) 2022 The Authors.
FAU - Yao, Weiqi
AU  - Yao W
AD  - Department of Hematology, Union Hospital, Tong Ji Medical College, Hua Zhong 
      University of Science and Technology, Hubei, China.
AD  - School of Biological Engineering and Food, Hubei University of Technology, Wuhan, 
      Hubei, China.
AD  - Wuhan Optics Valley Vcanbio Cell & Gene Technology Co., Ltd., Hubei, China.
AD  - Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., Hubei, China.
AD  - Hubei Engineering Research Center for Human Stem Cell Preparation, Application 
      and Resource Preservation, Wuhan, China.
FAU - Dong, Haibo
AU  - Dong H
AD  - Wuhan Optics Valley Vcanbio Cell & Gene Technology Co., Ltd., Hubei, China.
AD  - Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., Hubei, China.
AD  - Hubei Engineering Research Center for Human Stem Cell Preparation, Application 
      and Resource Preservation, Wuhan, China.
FAU - Qi, Ji
AU  - Qi J
AD  - Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., Hubei, China.
FAU - Zhang, Yu
AU  - Zhang Y
AD  - Wuhan Optics Valley Vcanbio Cell & Gene Technology Co., Ltd., Hubei, China.
AD  - Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., Hubei, China.
AD  - Hubei Engineering Research Center for Human Stem Cell Preparation, Application 
      and Resource Preservation, Wuhan, China.
AD  - VCANBIO Cell & Gene Engineering Corp., Ltd., No. 12 Meiyuan Road, Tianjin, China.
AD  - State Industrial Base for Stem Cell Engineering Products, Tianjin, China.
FAU - Shi, Lei
AU  - Shi L
AD  - Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA 
      General Hospital, National Clinical Research Center for Infectious Diseases, No. 
      100 Xi Si Huan Middle Road, Fengtai District, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20220709
PL  - England
TA  - EClinicalMedicine
JT  - EClinicalMedicine
JID - 101733727
PMC - PMC9270852
OTO - NOTNLM
OT  - Cellular therapy
OT  - Coronavirus disease-19 (COVID-19)
OT  - Mesenchymal stem cells
OT  - Meta-analysis
OT  - Systematic review
COIS- The authors declare that they have no competing interests.
EDAT- 2022/07/19 06:00
MHDA- 2022/07/19 06:01
PMCR- 2022/07/09
CRDT- 2022/07/18 03:41
PHST- 2022/03/07 00:00 [received]
PHST- 2022/06/16 00:00 [revised]
PHST- 2022/06/17 00:00 [accepted]
PHST- 2022/07/18 03:41 [entrez]
PHST- 2022/07/19 06:00 [pubmed]
PHST- 2022/07/19 06:01 [medline]
PHST- 2022/07/09 00:00 [pmc-release]
AID - S2589-5370(22)00275-9 [pii]
AID - 101545 [pii]
AID - 10.1016/j.eclinm.2022.101545 [doi]
PST - epublish
SO  - EClinicalMedicine. 2022 Jul 9;51:101545. doi: 10.1016/j.eclinm.2022.101545. 
      eCollection 2022 Sep.